

Spebrutinib

Catalog No: tcsc1482



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1202757-89-8

Formula:

$C_{22}H_{22}FN_5O_3$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

Btk

Purity / Grade:

>98%

Solubility:

DMSO : \geq 45 mg/mL (106.27 mM)

Alternative Names:

AVL-292;CC-292

Observed Molecular Weight:


423.44

Product Description

Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an **IC₅₀** of 0.5 nM.

IC50 & Target: IC50: [1]

In Vitro: Spebrutinib (CC-292) is a covalent, highly selective, orally active inhibitor of Btk with IC₅₀ value of 0.5 nM. Spebrutinib also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC₅₀s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, respectively. Extensive analysis has revealed that the EC₅₀ of Btk occupancy from a Spebrutinib dose-response in Ramos cells (EC₅₀=6 nM) correlated directly with the cellular EC₅₀ of Btk kinase inhibition with Spebrutinib (EC₅₀=8 nM). Furthermore, the concentration at which Spebrutinib inhibits 90% of Btk activity in Ramos cells is 35 nM while the concentration of Spebrutinib required for 90% occupancy of Btk is 39 nM^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!